BioCentury
ARTICLE | Company News

Impax, GSK terminating deal for PD compound

April 30, 2013 12:49 AM UTC

Impax Laboratories Inc. (NASDAQ:IPXL) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will end a 2010 deal granting the pharma exclusive rights to develop and commercialize idiopathic Parkinson's disease ...